Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.66 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | VNN1 | O95497 | 1/20 | 0.52 |
| ▸ | ACE | P12821 | 2/20 | 0.51 |
| ▸ | DPP4 | P27487 | 1/20 | 0.50 |
| ▸ | PREP | P48147 | 1/20 | 0.50 |
| ▸ | FAP | Q12884 | 1/20 | 0.50 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.50 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4893223 | 1.00 | ALDH1A1 (0.66) | ALDH1A1CA2VNN1ACEDPP4 | |
| SCHEMBL7592715 | 0.96 | ALDH1A1 (0.61) | ALDH1A1CA2VNN1ACEL3MBTL1 | |
| SCHEMBL10770319 | 0.88 | ALDH1A1 (0.51) | ALDH1A1VNN1DPP4PREPFAP | |
| SCHEMBL10770322 | 0.88 | ALDH1A1 (0.51) | ALDH1A1VNN1DPP4PREPFAP | |
| SCHEMBL6860849 | 0.86 | ALDH1A1 (0.50) | ALDH1A1CA2VNN1ACEDPP4 | |
| SCHEMBL10153787 | 0.84 | VNN1 (0.51) | ALDH1A1VNN1DPP4PREPFAP | |
| SCHEMBL2226633 | 0.84 | MMP2 (0.52) | ALDH1A1VNN1DPP4PREPFAP | |
| SCHEMBL13229 | 0.84 | CA2 (0.67) | ALDH1A1CA2L3MBTL1 | |
| SCHEMBL13230 | 0.84 | CA2 (0.67) | ALDH1A1CA2L3MBTL1 | |
| SCHEMBL28789388 | 0.84 | CA2 (0.67) | ALDH1A1CA2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9464053-B2 | Compositions for reducing Aβ 42 production and their use in treating alzheimer's disease (AD) | KAREUS THERAPEUTICS, SA (CH) | 2016-10-11 | — | — | US | disclosed |
| US-9464053-B2 | Compositions for reducing Aβ 42 production and their use in treating alzheimer's disease (AD) | KAREUS THERAPEUTICS, SA (CH) | 2016-10-11 | — | — | US | disclosed |
| US-9464053-B2 | Compositions for reducing Aβ 42 production and their use in treating alzheimer's disease (AD) | KAREUS THERAPEUTICS, SA (CH) | 2016-10-11 | — | — | US | disclosed |
| US-20140364457-A1 | COMPOSITIONS FOR REDUCING AB 42 PRODUCTION AND THEIR USE IN TREATING ALZHEIMER'S DISEASE (AD) | KAREUS THERAPEUTICS, SA (CH) | 2014-12-11 | — | — | US | disclosed |
| US-20140364457-A1 | COMPOSITIONS FOR REDUCING AB 42 PRODUCTION AND THEIR USE IN TREATING ALZHEIMER'S DISEASE (AD) | KAREUS THERAPEUTICS, SA (CH) | 2014-12-11 | — | — | US | disclosed |
| US-20140364457-A1 | COMPOSITIONS FOR REDUCING AB 42 PRODUCTION AND THEIR USE IN TREATING ALZHEIMER'S DISEASE (AD) | KAREUS THERAPEUTICS, SA (CH) | 2014-12-11 | — | — | US | disclosed |
| US-8846721-B2 | Compositions for reducing aβ 42 production and their use in treating alzheimer's disease (AD) | KAREUS THERAPEUTICS SA (CH) | 2014-09-30 | — | — | US | disclosed |
| US-8846721-B2 | Compositions for reducing aβ 42 production and their use in treating alzheimer's disease (AD) | KAREUS THERAPEUTICS SA (CH) | 2014-09-30 | — | — | US | disclosed |
| US-8846721-B2 | Compositions for reducing aβ 42 production and their use in treating alzheimer's disease (AD) | KAREUS THERAPEUTICS SA (CH) | 2014-09-30 | — | — | US | disclosed |
| US-20120322831-A1 | COMPOSITIONS FOR REDUCING AB 42 PRODUCTION AND THEIR USE IN TREATING ALZHEIMER'S DISEASE (AD) | KAREUS THERAPEUTICS SA (CH) | 2012-12-20 | — | — | US | disclosed |
| US-20120322831-A1 | COMPOSITIONS FOR REDUCING AB 42 PRODUCTION AND THEIR USE IN TREATING ALZHEIMER'S DISEASE (AD) | KAREUS THERAPEUTICS SA (CH) | 2012-12-20 | — | — | US | disclosed |
| US-20120322831-A1 | COMPOSITIONS FOR REDUCING AB 42 PRODUCTION AND THEIR USE IN TREATING ALZHEIMER'S DISEASE (AD) | KAREUS THERAPEUTICS SA (CH) | 2012-12-20 | — | — | US | disclosed |
| EP-2528898-A2 | NOVEL COMPOSITIONS FOR REDUCING Aß 42 PRODUCTION AND THEIR USE IN TREATING ALZHEIMER'S DISEASE (AD) | Kareus Therapeutics SA (FR) | 2012-12-05 | — | — | EP | disclosed |
| WO-2011089576-A2 | NOVEL COMPOSITIONS FOR REDUCING Aß 42 PRODUCTION AND THEIR USE IN TREATING ALZHEIMER'S DISEASE (AD) | KAREUS THERAPEUTTICS SA (CH) | 2011-07-28 | — | — | WO | disclosed |
| WO-2011089576-A2 | NOVEL COMPOSITIONS FOR REDUCING Aß 42 PRODUCTION AND THEIR USE IN TREATING ALZHEIMER'S DISEASE (AD) | KAREUS THERAPEUTTICS SA (CH) | 2011-07-28 | — | — | WO | disclosed |
| US-20080200512-A1 | Hepatitis C virus polymerase inhibitors | BLANEY JEFFREY MARK | 2008-08-21 | — | — | US | disclosed |
| US-6194426-B1 | CONTROLLING TUMOR NECROSIS FACTOR | RHONA-POULENC RORER S.A. (FR) | 2001-02-27 | — | — | US | disclosed |
| WO-1998025612-A1 | NOVEL THERAPEUTIC APPLICATION OF PYRROLE DERIVATIVES | RHONE-POULENC RORER S.A. (FR) | 1998-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200512-A1 | Hepatitis C virus polymerase inhibitors | SSU72, POLR2H, POLR2E | ALDH1A1 276/4885CA2 1113/4885VNN1 3849/4885 |
| US-20140364457-A1 | COMPOSITIONS FOR REDUCING AB 42 PRODUCTION AND THEIR USE IN TREATING ALZHEIMER'S DISEASE (AD) | PSEN2, APP, PSEN1 | ALDH1A1 2084/4885CA2 3679/4885VNN1 2173/4885 |
| US-20120322831-A1 | COMPOSITIONS FOR REDUCING AB 42 PRODUCTION AND THEIR USE IN TREATING ALZHEIMER'S DISEASE (AD) | PSEN2, APP, PSEN1 | ALDH1A1 2084/4885CA2 3679/4885VNN1 2173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.